Polyrizon files European patent for T&T platform

Polyrizon Ltd. filed a divisional European patent application for its Trap & Target (T&T) intranasal drug delivery platform, aiming to protect its advanced hydrogel-based system that prolongs drug residence time and contact with nasal mucosa.

Rhea-AI Filing Summary

Polyrizon Ltd. filed a divisional European patent application for its Trap & Target (T&T) intranasal drug delivery platform, aiming to protect its advanced hydrogel-based system that prolongs drug residence time and contact with nasal mucosa.

The filing aligns with a recently announced U.S. patent application covering Polyrizon’s two core technologies: Capture and Contain (C&C™), a nasal barrier against airborne biological threats, and T&T™, focused on enhancing bioavailability for local and systemic delivery of active pharmaceutical ingredients.

Key Figures

Press release date: April 27, 2026 Fiscal year reference: December 31, 2025 Core platforms: Two platforms

3 metrics

Press release date April 27, 2026 Date of announcement of European divisional patent application

Fiscal year reference December 31, 2025 Year-end referenced for the latest Form 20-F risk discussion

Core platforms Two platforms Capture and Contain (C&C™) and Trap and Target (T&T™)

Key Terms

divisional patent application, intranasal drug delivery, bioavailability, Capture and Contain (C&C™), +2 more

6 terms

divisional patent application regulatory

"today announced the filing of a divisional patent application with the Europe Patent Office"

A divisional patent application is a follow-up filing that splits out one or more distinct inventions from an earlier patent application while keeping the original filing date. Think of it like turning different chapters of a single cookbook into separate books so each can be protected; this helps companies secure broader or more targeted legal rights around a technology. For investors, divisionals matter because they strengthen a firm's defensive moat, extend the scope or life of protection, and reduce the risk of competitors copying key features.

intranasal drug delivery medical

"advanced intranasal drug delivery system, which is designed to enhance the effectiveness of medications"

Intranasal drug delivery is a method of giving medication through the nose so the active ingredient is absorbed across the nasal lining into the bloodstream or, in some cases, more directly into the brain. For investors, it matters because this route can speed onset, avoid breakdown in the digestive system, and enable treatments that would be hard or costly by injection or pills, potentially shortening development time, cutting costs, and opening new market opportunities.

bioavailability medical

"a novel approach to improving the bioavailability of active pharmaceutical ingredients (APIs)"

Bioavailability is the measure of how much and how quickly a substance, such as a medication or nutrient, enters the bloodstream and becomes available for use by the body. For investors, it matters because it influences how effectively a product works and how quickly results are seen, which can impact a company's success and the potential value of related investments. Think of it like how much of a medicine actually reaches your bloodstream after taking it—that determines how well it can do its job.

Capture and Contain (C&C™) technical

"encompasses key aspects of Polyrizon’s two core platform technologies: Capture and Contain (C&C™)"

Trap and Target (T&T™) technical

"Trap and Target (T&T™), designed for advanced nasal drug delivery"

forward-looking statements regulatory

"This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Polyrizon (PLRZ) announce in its latest Form 6-K?

Polyrizon announced it has filed a divisional European patent application for its Trap & Target (T&T) intranasal drug delivery platform, expanding protection around its hydrogel-based technology for enhancing drug residence time and mucosal contact in the nasal cavity.

What is Polyrizon’s Trap & Target (T&T) platform described in the 6-K?

Trap & Target (T&T) is Polyrizon’s intranasal drug delivery platform designed to improve bioavailability of active pharmaceutical ingredients by increasing nasal residence time and ensuring close contact with mucosal tissues for both local and systemic therapeutic applications.

How does the European patent application relate to Polyrizon’s U.S. IP strategy?

The European divisional patent application aligns with a recently announced U.S. patent application that covers key aspects of Polyrizon’s Capture and Contain (C&C™) and Trap and Target (T&T™) platforms, indicating a coordinated effort to build broader global intellectual property protection.

What therapeutic areas could Polyrizon’s T&T platform potentially address?

The T&T platform is positioned for intranasal delivery of drugs such as corticosteroids for allergic rhinitis, benzodiazepines for epileptic seizures, and naloxone for opioid overdose, targeting respiratory conditions, central nervous system disorders, and other medical needs through improved absorption.

What is Polyrizon’s Capture and Contain (C&C) technology?

Capture and Contain (C&C™) is a hydrogel technology forming a thin nasal barrier that adheres to mucosa and captures airborne biological threats, including allergens, viruses like influenza, and molds, aiming to prevent their penetration and protect nasal epithelial tissue from direct contact.

How does Polyrizon describe its overall business focus in this filing?

Polyrizon describes itself as a development-stage biotech company focused on innovative medical device hydrogels delivered as nasal sprays, creating a hydrogel-based shield that can block viruses and allergens while also being adapted for intranasal delivery of active pharmaceutical ingredients.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/27/2026 - 09:29 AM EDT Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of April 2026

Commission file number: 001-42375

Polyrizon Ltd.

(Translation of registrant’s name into English)

8 Ha-Pnina Street

Raanana, 4321545, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒         Form 40-F ☐

CONTENTS

Attached hereto and incorporated herein is the Registrant’s press release issued on April 27, 2026, titled “Polyrizon Announces Filing of European Patent Application for Its Breakthrough Drug Delivery Platform.”

EXHIBIT INDEX

Exhibit No.
99.1		Press release titled: “Polyrizon Announces Filing of European Patent Application for Its Breakthrough Drug Delivery Platform”

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Polyrizon Ltd.
Date: April 27, 2026	By:	/s/ Tomer Izraeli
	Name:	Tomer Izraeli
	Title:	Chief Executive Officer

2

Exhibit 99.1

Polyrizon Announces Filing of European Patent Application for Its Breakthrough Drug Delivery Platform

Raanana, Israel, April 27, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced the filing of a divisional patent application with the Europe Patent Office for its Trap & Target (T&T) platform technology. This application focuses exclusively on protecting the Company’s advanced intranasal drug delivery system, which is designed to enhance the effectiveness of medications by increasing their residence time and ensuring close contact with mucosal tissues and aligns with the Company’s recently announced U.S. patent application which encompasses key aspects of Polyrizon’s two core platform technologies: Capture and Contain (C&C™), a nasal blocker technology, and Trap and Target (T&T™), designed for advanced nasal drug delivery.

The T&T platform represents a significant advancement in intranasal drug delivery, offering a novel approach to improving the bioavailability of active pharmaceutical ingredients (APIs) and addressing critical challenges in both local and systemic drug delivery. The divisional patent application underscores Polyrizon’s commitment to securing comprehensive intellectual property protection for its innovative technology, which aim to revolutionize respiratory health and drug delivery.

Key Potential Features of the Trap & Target (T&T) Platform:

● Prolonged Residence Time: Enhancing the duration that drugs remain at the nasal absorption site, facilitating better absorption and efficacy.

● Improved Bioavailability: Increasing the amount of drug that reaches systemic circulation by bypassing first-pass metabolism and potentially improving therapeutic outcomes.

● Controlled Release: Allows for precise management of API release kinetics to ensure optimal therapeutic levels over time.

● Prevention of Dripping: The system is designed to prevent the formulation from dripping out of the nasal cavity to ensure maximum efficacy and patient comfort.

● Biodegradable Components: Utilizing safe and environmentally friendly biodegradable polymers .

● Versatility: Compatibility with a wide range of drug types, including small molecules, proteins, peptides, and antibodies, making it suitable for diverse therapeutic applications.

Tomer Izraeli, CEO of Polyrizon, commented: “The filing of this divisional patent application for our Trap & Target platform marks another important step in strengthening our global intellectual property portfolio. We believe that the T&T platform has the potential to transform intranasal drug delivery by improving the efficacy and safety of a wide range of medications. We are committed to advancing this innovative technology to address critical healthcare challenges and improve patient outcomes.”

The T&T platform leverages the nasal cavity’s rich vascularization to facilitate both local and systemic drug delivery, offering a promising solution for various therapeutic applications, such as corticosteroids for allergic rhinitis, benzodiazepines for epileptic seizures and naloxone for opioid overdose. By enhancing drug absorption and bioavailability, the platform has the potential to improve the treatment of respiratory conditions, central nervous system disorders, and other medical needs.

This application aligns with the Company’s recently announced U.S. patent application which encompasses key aspects of Polyrizon’s two core platform technologies: Capture and Contain (C&C™) and Trap and Target (T&T). The Capture and Contain (C&C™) platform utilizes a natural 3D polymeric network engineered to adhere optimally to the nasal mucosa. This advanced network forms a physical barrier that captures and contains airborne biological threats, such as allergens, viruses (such as Influenza), and molds, preventing their penetration and protecting the body.

About Polyrizon

Polyrizon is a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Polyrizon’s proprietary Capture and Contain ^TM, or C&C, hydrogel technology, comprised of a mixture of naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a “biological mask” with a thin shield containment barrier in the nasal cavity. Polyrizon are further developing certain aspects of our C&C hydrogel technology such as the bioadhesion and prolonged retention at the nasal deposition site for intranasal delivery of drugs. Polyrizon refers to its additional technology, which is in an earlier stage of pre-clinical development, that is focused on nasal delivery of active pharmaceutical ingredients, or APIs, as Trap and Target, or T&T. For more information, please visit https://polyrizon-biotech.com.

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses its commitment to securing comprehensive intellectual property protection for its innovative technology, which aim to revolutionize respiratory health and drug delivery, its belief that the T&T platform has the potential to transform intranasal drug delivery by improving the efficacy and safety of a wide range of medications, and its commitment to advancing this innovative technology to address critical healthcare challenges and improve patient outcomes. The Company cannot assure that any patent will issue as a result of a pending patent application or, if issued, whether it will issue in a form that will be advantageous to the Company.  Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s Annual Report on Form 20-F for the fiscal year ended December 31, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Polyrizon is not responsible for the contents of third-party websites.

Contacts:

Michal Efraty
Investor Relations
IR@polyrizon-biotech.com

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 PRESS RELEASE TITLED: "POLYRIZON ANNOUNCES FILING OF EUROPEAN PATENT APPLICATION 18.7 KB